HALLIE ELROD: Open Payments
NPI 1861277063 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,719 in 77 payments from 16 companies in 2025. Trend: 2023 $186 · 2024 $1,105 · 2025 $1,719
Food & beverage: $1,719
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $291 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $203 |
| GENZYME CORPORATION | 8 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $179 |
| Vifor Pharma, Inc. | 8 | $139 |
| Mallinckrodt Hospital Products Inc. | 7 | $138 |
| Grifols USA, LLC | 5 | $124 |
| GlaxoSmithKline, LLC. | 4 | $103 |
| Viatris Specialty LLC | 4 | $91 |
| Merck Sharp & Dohme LLC | 3 | $76 |
Products named: DUPIXENT, GLASSIA, OFEV, Zemaira, ACTHAR, Prolastin-C Liquid, TEZSPIRE, YUPELRI.
Industry payments across AL — which companies pay providers there.
